Company: INKT
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001193125-25-272532
Chunk: 2

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3
Chunk 2
---
 the base prospectus will be specified in a prospectus supplement to the base prospectus. The prospectus supplement immediately follows the base prospectus. The $150,000,000 of shares of common stock that may be offered, issued and sold under the prospectus supplement is included in the $50,000,000 of securities that may be offered, issued and sold by us under the base prospectus. Upon termination of the At Market Issuance Sales Agreement with B. Riley Securities, Inc., any portion of the $50,000,000 included in the prospectus supplement that is not sold pursuant to the At Market Issuance Sales Agreement will be available for sale in other offerings pursuant to the base prospectus, and if no shares of common stock are sold under the At Market Issuance Sales Agreement, the full $150,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.

The information contained in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where such offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED NOVEMBER 7, 2025 PROSPECTUS MiNK Therapeutics, Inc. $150,000,000 Common Stock Preferred Stock Warrants Debt Securities Units We may offer to the public from time to time in one or more series or issuances:

| • |     | common stock; |

| • |     | preferred stock; |

| • |     | warrants to purchase our common stock, preferred stock or debt securities; |

| • |     | debt securities consisting of debentures, notes or other evidences of indebtedness; |

| • |     | units consisting of a combination of the foregoing securities; or |

| • |     | any combination of these securities. |

The aggregate initial offering price of all securities sold by us pursuant to this prospectus will not exceed $150,000,000. This prospectus provides a general description of the securities that we may offer. Each time that we offer securities under this prospectus, we will provide the specific terms of the securities offered, including the public offering price, in a supplement to this prospectus. Any prospectus supplement may add to, update or change information contained in this prospectus. You